We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The National Institutes of Health is sponsoring a clinical trial of Gilead Sciences’ antiviral remdesivir combined with Eli Lilly’s anti-inflammatory Olumiant (baricitinib) for treatment of COVID-19 infections. Read More
The partners expect that the therapy will be offered as a prophylactic for those returning to work and as a therapeutic for those who have been exposed to the coronavirus. Read More
California biotech firm Sorrento Therapeutics and New York City’s Mount Sinai Health System are teaming up to test and develop a triple antibody cocktail that could potentially treat or help prevent COVID-19. Read More
Moderna, a frontrunner in the race to develop a COVID-19 vaccine, announced Thursday that its phase 3 study for the candidate could start by early summer. Read More
A failed study of nearly 1,400 COVID-19 patients taking hydroxychloroquine is the latest to cast doubt on the drug’s benefit as a coronavirus treatment. Read More
Incyte and Novartis are planning a second phase 3 clinical trial in the U.S. of their JAK inhibitor Jakafi (ruxolitinib) as a COVID-19 treatment. Read More